Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215312 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin
A Phase 2 study of Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT07215312 is a Phase 2 study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 100 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT07215312, a Phase 2 study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Conditions Studied
Interventions
- DRUG LY3938577
- DRUG Degludec
Study Locations (20)
Texas
- Texas Diabetes & Endocrinology, P.A. - Austin
- Velocity Clinical Research, Dallas - Dallas
- Juno Research - Houston
- Southern Endocrinology Associates - Mesquite
- Consano Clinical Research, LLC - Shavano Park
- Texas Valley Clinical Research - Weslaco
Florida
- Tampa Bay Medical Research - Clearwater
- Encore Medical Research - Hollywood
- Clinical Research of Central Florida - Lakeland
- Encore Medical Research - Weston - Weston
California
- Encompass Clinical Research - Spring Valley
- University Clinical Investigators, Inc. - Tustin
Arizona
- Tucson Clinical Research Institute - Tucson
Iowa
- Iowa Diabetes and Endocrinology Research Center - West Des Moines
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Accellacare - Wilmington - Wilmington
Oklahoma
- AMR Clinical - Norman
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07215312
The ClinicalTrials.gov registry entry for NCT07215312 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which LY3938577 is the first listed.
NCT07215312 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT07215312 about?
NCT07215312 is a clinical study titled "A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin". The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
What is the current status of trial NCT07215312?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2025-10-13. Estimated completion is 2026-12.
What conditions does trial NCT07215312 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT07215312?
The interventions under investigation include: LY3938577 (DRUG), Degludec (DRUG).
Who is sponsoring clinical trial NCT07215312?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215312 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Iowa, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
DETERMINE: Detemir vs NPH
RECRUITING · Phase 2
-
MANAGe-DM: Novel Nurse Case Management to Improve Diabetes Outcomes in Formerly Incarcerated Black Men
RECRUITING · Phase 2
-
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
RECRUITING · Phase 2
-
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
ACTIVE NOT RECRUITING · Phase 2
-
Addressing Basic Needs to Improve Diabetes Outcomes in Medicaid Beneficiaries
ACTIVE NOT RECRUITING · Phase 2
-
Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.